FibroGen, Inc.
FGEN
$10.48
$0.131.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 832.14% | 47.77% | 62.02% | -100.72% | -105.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 832.14% | 47.77% | 62.02% | -100.72% | -105.60% |
| Cost of Revenue | -78.95% | -74.56% | -59.89% | -42.93% | -33.06% |
| Gross Profit | 104.75% | 92.99% | 82.87% | -21.49% | -20.31% |
| SG&A Expenses | -22.01% | -29.03% | -33.49% | -68.60% | -64.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.37% | -65.43% | -53.90% | -51.29% | -43.04% |
| Operating Income | 88.39% | 78.67% | 70.11% | 24.05% | 17.83% |
| Income Before Tax | 77.94% | 69.60% | 62.21% | 29.07% | 20.82% |
| Income Tax Expenses | 79.18% | 16.93% | -3.17% | -1,509.68% | -698.36% |
| Earnings from Continuing Operations | 77.94% | 69.66% | 62.26% | 29.23% | 20.94% |
| Earnings from Discontinued Operations | 13.57% | 394.03% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.77% | 95.84% | 83.26% | 58.60% | 47.76% |
| EBIT | 88.39% | 78.67% | 70.11% | 24.05% | 17.83% |
| EBITDA | 88.76% | 78.85% | 70.03% | 22.59% | 16.80% |
| EPS Basic | 98.77% | 95.85% | 83.58% | 59.90% | 49.71% |
| Normalized Basic EPS | 86.74% | 77.62% | 70.05% | 25.62% | 19.93% |
| EPS Diluted | 98.77% | 95.85% | 83.58% | 59.90% | 49.71% |
| Normalized Diluted EPS | 86.74% | 77.62% | 70.05% | 25.62% | 19.93% |
| Average Basic Shares Outstanding | 2.28% | 2.51% | 3.14% | 3.10% | 3.72% |
| Average Diluted Shares Outstanding | 2.28% | 2.51% | 3.14% | 3.10% | 3.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |